Notable Labs Announces Addition of Thomas Bock to Board of Directors

FOSTER CITY, Calif. – Oct. 13, 2020 – Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, today announced the addition of Thomas A. Bock to its board of directors.

Notable Labs Enters Into Partnership With myTomorrows

FOSTER CITY, Calif., Sep. 24, 2020 – Notable, a functional precision medicine company, and myTomorrows, an integrated platform that links patients with an unmet medical need to treatments in development worldwide, are proud to announce their partnership.

Notable Launches New Clinical Study With Washington University School of Medicine Exploring Ex Vivo Drug Screening to Predict Chemotherapy Sensitivity and Resistance

FOSTER CITY, CALIF. – Aug. 06, 2020 – Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, announced a new precision oncology study with Washington University School of Medicine in St. Louis, exploring the feasibility of ex vivo drug screening to predict sensitivity and resistance to chemotherapy, and to identify novel synergies across a broad panel of anti-cancer therapies.

Stanford study finds that Notable’s drug sensitivity screening platform can identify potentially useful drugs for MDS patients refractory to standard therapies

FOSTER CITY, Calif., June 23, 2020 (GLOBE NEWSWIRE) — Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, announced today that the results of a Stanford study using its drug sensitivity screening platform have been published in Blood Advances (June 23, 2020; Volume 4, Issue 12).

Notable and MDS Foundation Announce Partnership to Collaborate on Clinical MDS Trials and Advance Drug Therapies for MDS Patients

Foster City, CA – April 30, 2020 — Notable, which is redefining cancer treatment with its scientific technology platform to rapidly advance drug development, announced a partnership today with the MDS Foundation. MDS Foundation (MDSF) provides insight and information to families on upcoming clinical trials for myelodysplastic syndrome (MDS). As part of the partnership, Notable […]

Notable Announces Leadership Team Expansion

SAN FRANCISCO, April 09, 2020 (GLOBE NEWSWIRE) — Notable, a technology leader redefining cancer treatment through rapid drug development via a clinically validated platform, announced today its board has appointed veteran life science executive Laurie Heilmann as Chief Executive Officer. She succeeds founder Matt De Silva who will remain a member of Notable’s Board of […]

MedTech Notable Labs launches rolling blood cancer trial to test its AI system

Precision oncology firm Notable Labs is launching its first self-sponsored clinical trial, designed from the ground up to help validate its cancer patient matching platform over the long term. The observational study—which also represents the company’s largest trial to date—aims to enroll up to 1,000 participants with a variety of blood cancers and will follow […]

The 50 best workplaces for innovators

It’s not about the perks. For Fast Company‘s inaugural Best Workplaces for Innovators list, we set out to find companies that empower all employees—not just top executives, scientists, or coders—to create new products, improve operations, and take risks. We searched for businesses where innovation isn’t just a buzzword but a part of the value system […]

Notable Named To Fast Company’s Inaugural List Of The 50 Best Workplaces for Innovators

SAN FRANCISCO, Aug. 05, 2019 (GLOBE NEWSWIRE) — Notable, which is redefining cancer treatment with a clinically validated platform that rapidly advances cancer drug development at a fraction of the traditional time and cost, announced today that it has been named to Fast Company’s inaugural Best Workplaces for Innovators list, honoring businesses and organizations that […]

Cancer Drug Discovery Firm Notable Nabs $40M in Series B Funding Round

NEW YORK – Notable, a Bay Area firm using automated laboratory testing, artificial intelligence, and single-cell omics for cancer drug discovery, said yesterday that it has raised $40 million in a Series B financing round to accelerate the development of its services. The financing was co-led by B Capital Group and returning investor LifeForce Capital. […]